First Quarter 2013 Highlights:
• Total revenues increased 762% to $240,420 from $27,884
• Recorded $125,000 license and service revenues from international customers
• Gross profit increased 1133%; gross margins up from 54.4% to 77.9%
• Reduced interest expense by 56%
• Net loss per share for the quarter down from $.02 to $.007
By Zacks Small Cap Research...
In January 2013, we initiated coverage of OxySure Systems, Inc. with an Outperform rating and price target of $1.75 per share. We believe that the company’s Model 615 Emergency Oxygen System is a potential breakthrough product for the delivery of medical oxygen in a medical emergency required supplemental oxygen, such as a cardiac arrest or acute asthma attack. We see several distinctive advantages of the Model 615 over portal oxygen cylinders, which are typically not designed for emergency use.
Firstly, with the Model 615 unit, oxygen is generated on demand from two inert dry powders. There is no storage of oxygen, no compressed tanks, no dials, no valves, no regulatory maintenance, no hydrostatic testing, no batteries, no required training, and none of the hazards associated with traditional oxygen provision systems.
Secondly, the OxySure Model 615 is safe and simple to use, and provides oxygen instantly with the turn of a #$%$. It can be used by any lay person, and bridges the gap between the onset of a medical emergency and the time that the first responders arrive on the scene. In the U.S., that gap between calling 911 and emergency medical professionals arriving is 6 to 15 minutes, depending on traffic conditions and other factors. If the medical emergency is of a cardiovascular nature, this gap can be critical, since irreparable damage to brain tissue can occur starting after only three minutes of oxygen deprivation.
And finally, the OxySure Model 615 is the perfect adjunct product to be placed next to an automated external defibrillator (AED). AED market growth over the past several years has been impressive.
FRISCO, TX--(Marketwire - April 01, 2013) - OxySure® Systems, Inc. (OXYS) ("OxySure," or the "Company"), today reported financial and operating results for the fourth quarter and year ended December 31, 2012.
Fiscal Year 2012 Highlights:
Revenues increased 46%, led by an 43% increase in product sales in the United States
Gross profit increased 113%; gross margins up from 44.2% to 64.6%
General & administrative expenses down 14%
Interest expense down by $401,594 or 66%
Notes payable decreased by $2,252,789
Stockholder equity increased by $2,125,014
Cash outflows from operations increased by $569,004
Net loss per share for the year down from $.10 to $.04
FRISCO, Texas, and Irvine, California, March 26, 2013 (GLOBE NEWSWIRE) -- OxySure(R) Systems, Inc. (OXYS: OTCQB) ("OxySure," or the "Company"), a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology, today announced that Mr. Jeremy M. (“Jerry”) Jones, former Chairman and CEO of Apria Healthcare has joined the Company as an independent director effective April 1, 2013.
Mr. Jones brings over 35 years of healthcare industry experience to the OxySure Board. Mr. Jones founded Homedco Group, Inc., a home healthcare services company, which he took public in 1991. Homedco merged into Apria Healthcare Group, Inc. (“Apria”) in 1995 and from 1995 through January 1998, Mr. Jones was Chief Executive Officer and Chairman of Apria, which became the largest homecare service provider in the nation under his leadership through merger, acquisitions and increased market dominance, and was sold to the Blackstone Group (NYSE: BX) for $1.7 billion in December 1998. Mr. Jones currently serves as Chairman of On Assignment, Inc. (NYSE: ASGN), a $1.3 billion leader in the healthcare and life sciences sectors focusing on in-demand, skilled medical and technical staffing. At On Assignment he also serves on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
FRISCO, Texas and SYDNEY, March 4, 2013 -- OxySure(R) Systems, Inc., a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology is pleased to announce that the Company has entered into an exclusive distribution agreement with Aero Health Holdings Limited ("Aero Australia") to distribute OxySure's products in Australia and New Zealand. Simultaneously, the Company entered into an exclusive distribution agreement with Aero Healthcare Limited ("Aero UK") to distribute OxySure's products in the United Kingdom.
FRISCO, Texas, Feb 26, 2013 -- OxySure(R) Systems, Inc., a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology is excited to announce that in excess of 2,000 saves have been estimated in connection with the use of its flagship product, the OxySure Model 615 emergency oxygen device.
A 'save' is regarded as an incident during which Model 615 was used to assist someone in a medical emergency or other distress situation. Examples of such situations vary widely, and can include serious incidents such as cardiac arrest (in which OxySure is used post-resuscitation), as well as events such as asthma attacks, COPD exacerbations, allergy attacks, heat exhaustion, hypoxia/altitude sickness, migraine attacks, poisoning/overdose, diabetic emergencies, smoke inhalation, seizures, chest pain, fainting, dehydration, near drowning, hyperthermia, injury with trauma, and the treatment of shock. The standard of care in most medical emergencies is for first responders to provide supplemental oxygen to patients typically immediately upon arrival. OxySure's Model 615 allows lay rescuers to begin sooner, thereby bridging the gap until professional responders arrive on the scene and can provide more advanced care.
"The OxySure Model 615 enables a loved one, bystander or even the person him/herself to provide oxygen, awaiting the arrival of emergency medical responders," stated Dr. Vincent Mosesso, Medical Director of pre-hospital care services for the University of Pittsburgh Medical Center (UPMC), and also co-founder and Medical Director of the National Center for Early Defibrillation, now called Sudden Cardiac Arrest Association.
"We are indeed thrilled by the phenomenal usage validation our product has enjoyed in a very short period of time," stated Julian Ross, CEO of OxySure. "We believe that as our installed base continues to grow the usage will grow significantly, as will the comfort level and awareness of the product by our customers."
"OxySure is going to increase that golden window of opportunity when things have to be done immediately to ensure survival," stated Dr. James R. Winn, former CEO of the Federation of State Medical Boards of the United States.